The U.S. stock market has been on a notable upswing, with the S&P 500 and Nasdaq reaching record highs following positive employment data that bolstered confidence in economic strength. For investors exploring beyond the well-known giants, penny stocks—typically smaller or newer companies—can offer intriguing opportunities despite their somewhat antiquated name. These stocks can provide surprising value when based on solid financials, and we will explore three examples that showcase potential for significant returns while maintaining balance sheet strength.

Top 10 Penny Stocks In The United States

Click here to see the full list of 711 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

BioNexus Gene Lab (NasdaqCM:BGLC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: BioNexus Gene Lab Corp., with a market cap of $5.77 million, operates through its subsidiary to sell chemical raw material products across Malaysia, Indonesia, Vietnam, and other Southeast Asian countries.

Operations: The company's revenue is derived from two segments: MRNA Scientific, contributing $0.01 million, and Chemrex Corporation, generating $9.25 million.

Market Cap: $5.77M

BioNexus Gene Lab Corp., with a market cap of US$5.77 million, faces challenges typical of penny stocks, including volatility and financial instability. Despite generating US$9.25 million in revenue from Chemrex Corporation, it remains unprofitable with increasing losses over the past five years. The company has sufficient cash runway for more than a year but struggles with compliance issues, leading to potential delisting from Nasdaq due to its low share price. Recent strategic moves include a partnership with Shenzhen Rongguang Health Group aimed at expanding cancer screening capabilities and developing advanced healthcare technologies in Southeast Asia and China.

• Click here and access our complete financial health analysis report to understand the dynamics of BioNexus Gene Lab.
• Understand BioNexus Gene Lab's track record by examining our performance history report.

Nephros (NasdaqCM:NEPH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Nephros, Inc. is a commercial-stage company that develops and sells water solutions to the medical and commercial markets in the United States, with a market cap of $16.98 million.

Operations: The company's revenue from its Water Filtration segment, excluding Pathogen Detection, amounts to $13.55 million.

Market Cap: $16.98M

Nephros, Inc., with a market cap of US$16.98 million, is navigating the complexities of penny stocks by focusing on water filtration solutions. Despite being unprofitable, it reported a net income of US$0.183 million for Q3 2024, marking an improvement from the previous year's loss. The company’s debt-free status and stable cash runway are positive indicators amidst its financial challenges. Recent product innovations like the HydraGuard 20 UltraFilter aim to capture new market opportunities by meeting stringent water quality standards, potentially bolstering future revenue streams and supporting compliance in medical and pharmaceutical industries.

• Unlock comprehensive insights into our analysis of Nephros stock in this financial health report.
• Assess Nephros' future earnings estimates with our detailed growth reports.

Rafael Holdings (NYSE:RFL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Rafael Holdings, Inc. primarily holds interests in clinical and early-stage pharmaceutical companies as well as commercial real estate assets in the United States and Israel, with a market cap of $44.91 million.

Operations: The company's revenue is derived from its Real Estate segment, which generated $0.28 million, and its Infusion Technology segment, contributing $0.36 million.

Market Cap: $44.91M

Rafael Holdings, Inc., with a market cap of US$44.91 million, is navigating the penny stock landscape with interests in pharmaceuticals and real estate. The company remains pre-revenue, generating less than US$1 million in sales. Despite having more cash than debt and covering both short- and long-term liabilities with its assets, Rafael faces challenges such as a negative return on equity (-75.36%) and increased losses over five years at 8.9% annually. Recent earnings showed a net loss of US$4.47 million for Q4 2024, alongside delayed SEC filings that may concern investors about financial transparency.

• Navigate through the intricacies of Rafael Holdings with our comprehensive balance sheet health report here.
• Explore historical data to track Rafael Holdings' performance over time in our past results report.

Turning Ideas Into Actions

• Dive into all 711 of the US Penny Stocks we have identified here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com